Literature DB >> 25564171

Overutilization and Cost of Advanced Imaging for Long-Bone Cartilaginous Lesions.

Robert J Wilson1, Justin W Zumsteg2, Katherine A Hartley3, Justin H Long4, Nathan W Mesko5, Jennifer L Halpern6, Herbert S Schwartz7, Ginger E Holt8.   

Abstract

BACKGROUND: The prevalence and cost of unnecessary advanced imaging studies (AIS) in the evaluation of long bone cartilaginous lesions have not been studied previously.
METHODS: A total of 105 enchondromas and 19 chondrosarcomas arising in long bones from July 2008 until April 2012 in 121 patients were reviewed. Advanced imaging was defined as MRI, CT, bone scan, skeletal survey, or CT biopsy. Two blinded radiologists independently reviewed the initial imaging study and determined if further imaging was indicated based on that imaging study alone. The cost of imaging was taken from our institution's global charge list. Imaging was deemed unnecessary if it was not recommended by our radiologists after review of the initial imaging study. The difference in cost was calculated by subtracting the cost of imaging recommended by each radiologist from the cost of unnecessary imaging. The sensitivity and specificity for distinguishing enchondromas from chondrosarcomas was calculated. A minimum of 2 years from diagnosis of an enchondroma was required to monitor for malignant transformation.
RESULTS: Of patients diagnosed with an enchondroma, 85 % presented with AIS. The average enchondroma patient presented with one unnecessary AIS. The radiologists' interpretations agreed 85 % of the time for enchondromas and 100 % for chondrosarcomas. The sensitivity and specificity for distinguishing enchondromas from chondrosarcomas was 95 % for one radiologist and 87 and 95 % for the other. The average unnecessary cost per enchondroma patient was $1,346.18.
CONCLUSIONS: Unnecessary AIS are frequently performed and are a significant source of expense. The imaging algorithms outlined in this study may reduce unnecessary AIS.

Entities:  

Mesh:

Year:  2015        PMID: 25564171     DOI: 10.1245/s10434-014-4325-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  The incidence and outcome of chondral tumours as incidental findings on investigation of shoulder pathology.

Authors:  S S Jassim; T Hilton; A Saifuddin; R Pollock
Journal:  Eur J Orthop Surg Traumatol       Date:  2019-08-17

2.  Radiographic Enchondroma Surveillance: Assessing Clinical Outcomes and Costs Effectiveness.

Authors:  Craig C Akoh; Ethan Craig; Alexander M Troester; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2019

3.  The Impact of Pre-Referral Advanced Diagnostic Testing on Wait Time to See a Hand Surgeon for Common Upper-Extremity Conditions.

Authors:  Yu-Ting Lu; Steven C Haase; Ting-Ting Chung; Kevin C Chung; Erika D Sears
Journal:  J Hand Surg Am       Date:  2019-10-31       Impact factor: 2.230

4.  The changing face of central chondrosarcoma of bone. One UK-based orthopaedic oncology unit's experience of 33 years referrals.

Authors:  A Mark Davies; Anish Patel; Rajesh Botchu; Christine Azzopardi; Steven James; Lee Jeys
Journal:  J Clin Orthop Trauma       Date:  2021-02-27

Review 5.  Characterizing and quantifying low-value diagnostic imaging internationally: a scoping review.

Authors:  Elin Kjelle; Eivind Richter Andersen; Arne Magnus Krokeide; Lesley J J Soril; Leti van Bodegom-Vos; Fiona M Clement; Bjørn Morten Hofmann
Journal:  BMC Med Imaging       Date:  2022-04-21       Impact factor: 2.795

6.  Enchondromas and atypical cartilaginous tumors at the proximal humerus treated with intralesional resection and bone cement filling with or without osteosynthesis: retrospective analysis of 42 cases with 6 years mean follow-up.

Authors:  Georg W Omlor; Vera Lohnherr; Jessica Lange; Simone Gantz; Christian Merle; Joerg Fellenberg; Patric Raiss; Burkhard Lehner
Journal:  World J Surg Oncol       Date:  2018-07-13       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.